IP Library Granted Patent US 12667595
Granted Patent B2
US 12667595 · App. 18/168,526 · Granted Jun 30, 2026

Composition for preventing, improving or treating benign prostatic hyperplasia or alopecia, comprising heat-killed probiotics as active ingredient

Inventors: Eun Kyung Kim (Chungju-si, KR); Kwon Il Han (Wonju-si, KR); Masahiro Iwasa (Wonju-si, KR); Young Jin Choi (Hwaseong-si, KR); Meiqi Fan (Chungju-si, KR)
Assignee: BEREUM CO., LTD
A61K35/742A23L33/135A61P13/08A61P17/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12667595
App. No.
18/168,526
Granted
Jun 30, 2026
Kind
B2
Abstract

Provided is a pharmaceutical composition for preventing or treating benign prostatic hyperplasia or alopecia, comprising lactic acid bacteria of Enterococcus genus as an active ingredient. The pharmaceutical composition of the present invention can replace the conventional therapeutic agents against treating benign prostatic hyperplasia or alopecia, such as finasteride or dutasteride. In particular, by introducing heat-killed probiotics of Enterococcus faecalis , the effect of preventing or treating benign prostatic hyperplasia or alopecia can be further enhanced.

Claims (4)

1 . A method of treating benign prostatic hyperplasia (BPH) in a subject, the method comprising orally administering to the subject a composition comprising heat-killed probiotics of Enterococcus faecalis EF-2001 as an active ingredient.

2 . The method of claim 1 , wherein the administering reduces expression of an androgen receptor (AR) signaling factor selected from estrogen receptors (ER), androgen receptor (AR), and prostate specific antigen (PSA).

3 . The method of claim 1 , wherein the administering increases expression of Bax and/or decreases expression of Bcl-2 in prostate tissue.

4 . The method of claim 1 , wherein the administering reduces expression of a proliferation marker selected from proliferating cell nuclear antigen (PCNA) and Cyclin D1.